The study investigated the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus metformin on pregnancy rates in women with polycystic ovary syndrome (PCOS). The research aimed to determine if GLP-1RA-based therapy improved reproductive outcomes in this population.
Key Clinical Findings
A systematic review and meta-analysis of randomized trials was conducted, encompassing data from three trials involving 252 participants. The search included PubMed, Scopus, and Web of Science from their inception to February 2026. The study focused on trials comparing GLP-1RA-based therapy, either alone or combined with metformin, to metformin monotherapy in women diagnosed with PCOS. Four reports from the three randomized trials were included in the analysis. GLP-1RA-based treatment did not significantly improve overall pregnancy rates. However, it was associated with an increase in natural pregnancy rates. The effect on in vitro fertilization (IVF) pregnancy was not significant. Trial sequential analysis supported the finding for natural pregnancy, while the evidence for overall pregnancy was underpowered.
Evidence Certainty and Conclusions
The certainty of evidence was rated as moderate for natural pregnancy and low for the other outcomes. The study concluded that GLP-1 receptor agonists show preliminary signals for improving spontaneous conception in women with PCOS. However, the available evidence remains limited, and current evidence is insufficient to draw conclusions regarding IVF outcomes. Larger trials with standardized endpoints, including live birth, are needed.